|

Nivolumab Injection Clinical Trials

2 actively recruiting trials

Also known as: OPDIVO, adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University Hospital, Lille1
  • CNBG-Virogin Biotech (Shanghai) Ltd.1

Indications

  • Cancer2
  • Malignant Pleural Mesothelioma1
  • Metastatic Gastric Cancer1
  • Mesotheliomas Pleural1
  • Lung Cancer1

Other2 trials

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Phase 1/2
The IMmunotherapy Pleural 5-ALA PDT
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.